Annabel Samimy
Stock Analyst at Stifel
(4.38)
# 315
Out of 5,146 analysts
56
Total ratings
45.28%
Success rate
34.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Buy | $20 → $17 | $4.50 | +277.78% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $11.36 | +58.45% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $56.32 | -2.34% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $8.53 | +427.55% | 3 | Dec 19, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $35 → $40 | $29.56 | +35.32% | 2 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $29.23 | +77.90% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $35.64 | +40.29% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $21.42 | +124.09% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $191.39 | +20.17% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $66.53 | +35.28% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $128.60 | +12.75% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.56 | +294.74% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $6.82 | +149.27% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $9.31 | +93.34% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $12.32 | +94.81% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $33.12 | +141.55% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $196.83 | +16.85% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.35 | +1,677.78% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.25 | +33,233.33% | 3 | Apr 16, 2020 |
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $4.50
Upside: +277.78%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $11.36
Upside: +58.45%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $56.32
Upside: -2.34%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $8.53
Upside: +427.55%
Oculis Holding AG
Dec 19, 2025
Maintains: Buy
Price Target: $35 → $40
Current: $29.56
Upside: +35.32%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $29.23
Upside: +77.90%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $35.64
Upside: +40.29%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $21.42
Upside: +124.09%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $191.39
Upside: +20.17%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $66.53
Upside: +35.28%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $128.60
Upside: +12.75%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $4.56
Upside: +294.74%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $6.82
Upside: +149.27%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $9.31
Upside: +93.34%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $12.32
Upside: +94.81%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $33.12
Upside: +141.55%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $196.83
Upside: +16.85%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.35
Upside: +1,677.78%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.25
Upside: +33,233.33%